Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen 

Slides:



Advertisements
Similar presentations
125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy  Mira Keyes, MD, Tom Pickles, MD, Alexander Agranovich, MD, Winkle.
Advertisements

Judith Bosschieter, André N. Vis, Henk G. van der Poel, Luc M
Pascal Rischmann  European Urology Supplements 
Volume 71, Issue 2, Pages (February 2017)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Management of Acute and Chronic Retention in Men
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Volume 71, Issue 2, Pages (February 2017)
Prostate Cancer Epidemic in Sight?
Rowland Illing  European Urology Supplements 
Bladder Cancer: A Major Public Health Issue
Back to the Future: Introduction and Conclusions
Volume 52, Issue 3, Pages (September 2007)
What is New in Hormone Therapy for Prostate Cancer in 2007?
European Urology Oncology
Rowland Illing  European Urology Supplements 
Volume 70, Issue 5, Pages (November 2016)
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Tillmann Loch, Pat Fox Fulgham  European Urology 
Richard C. Harkaway  European Urology Supplements 
Volume 50, Issue 3, Pages (September 2006)
Volume 50, Issue 5, Pages (November 2006)
Tim Schneider  European Urology Supplements 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Transurethral Resection of the Prostate
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
The Importance of Testosterone Control in Prostate Cancer
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Volume 54, Issue 6, Pages (December 2008)
When to Treat the Prostate, the Bladder, or Both?
Long-Term Hormonal Therapy: Who Would Benefit?
Simultaneous integrated prophylactic cranial irradiation in sino-nasal cancer  Kenneth Jensen, Maja Bendtsen Sharma, Simon Lenler-Eriksen, Per Friis, Anne.
Volume 65, Issue 3, Pages (March 2014)
Pharmacotherapy in Stress and Mixed Incontinence
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Christian Stief  European Urology Supplements 
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Improving Flexibility and Quality of Life for Your Patients: A Must?
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
LUTS and Sexual Dysfunction: Implications for Management of BPH
Management of Prostate Cancer: Global Strategies
C.G Roehrborn, T McNicholas  European Urology Supplements 
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Cone beam CT based dose calculation in the thorax region
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
Technical Innovations and Patient Support in Radiation Oncology
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Physical Function in Patients with Cancer
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Technical Innovations and Patient Support in Radiation Oncology
Michael Marberger  European Urology Supplements 
Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette 
Presentation transcript:

Predicting Urinary Morbidity after Brachytherapy of Localized Prostate Cancer  Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen  European Urology Supplements  Volume 7, Issue 12, Pages 723-731 (November 2008) DOI: 10.1016/j.eursup.2008.07.004 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 International Prostate Symptom Score (IPSS) as a function of postimplant time interval published by different authors [4,10,15,18,21]. * Indicates a study with mean IPSS values. ** Indicates a study with median IPSS values. Note: 0 mo represents the situation before treatment. European Urology Supplements 2008 7, 723-731DOI: (10.1016/j.eursup.2008.07.004) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Transversal ultrasound image through the midgland. (a) “Peripheral” loading of the seeds to spare the urethra; dose at the center of the urethra is 197Gy. (b) “Uniform” loading of the seeds; the needle at D3.5 is likely to puncture the urethra; dose at the center of the urethra is 330Gy. Legend: White line, prostate contour; orange line, 145Gy isodose; light green line, 290Gy isodose; blue line, 72.5Gy isodose; dark green line, urethra contour; orange dots, I-125 seed sources. European Urology Supplements 2008 7, 723-731DOI: (10.1016/j.eursup.2008.07.004) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Dose build-up implant with I-125 sources and Pd-103 sources. Because of the shorter half-value time of Pd-103 (17 d) compared with I-125 (60 d), the dose builds up much faster in prostates implanted with Pd-103; consequently, the radiation dose is expected to take effect earlier. Greater biologic effectiveness requires a lower total dose when applying Pd-103 (usually 125Gy) than when applying I-125 (usually 145Gy). European Urology Supplements 2008 7, 723-731DOI: (10.1016/j.eursup.2008.07.004) Copyright © 2008 European Association of Urology Terms and Conditions